WO1995014681A1 - Isoxazoline compounds as antiinflammatory agents - Google Patents
Isoxazoline compounds as antiinflammatory agents Download PDFInfo
- Publication number
- WO1995014681A1 WO1995014681A1 PCT/IB1994/000333 IB9400333W WO9514681A1 WO 1995014681 A1 WO1995014681 A1 WO 1995014681A1 IB 9400333 W IB9400333 W IB 9400333W WO 9514681 A1 WO9514681 A1 WO 9514681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- carbons
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to a series of 3-aryl-2-isoxazoline-5-hydroxamic acid compounds which are selective inhibitors of phosphodiesterase type IV (PDE ⁇ ) and as such are useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis and other inflammatory conditions.
- PDE ⁇ phosphodiesterase type IV
- This invention also relates to the pharmaceutically acceptable salts of said compounds; to a method of using such compounds in inhibiting PDE, V , and in the treatment of inflammatory conditions, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis and dermatitis in mammals, especially humans; and to pharmaceutical compositions useful therefor.
- the "inflammatory conditions" which can be treated according to this invention include, but are not limited to, chronic obstructive pulmonary disease, shock, atopic dermatitis, bronchitis, rheumatoid arthritis and osteoarthritis.
- Certain pyrimidone compounds have been disclosed to be useful as antidepres- sants by Saccomano et al., in European Patent Application EPO 247725 A2 published December 2, 1987. The same pyrimidone compounds have been disclosed to be useful against asthma and certain skin disorders in International Patent Application No. PCT/US90/02162, published May 30, 1991 as International Publication Number WO 91/07178. Summary of the Invention
- This invention is concerned with a series of 3-aryl-2-isoxazoline-5-hydroxamic acid compounds and to the pharmaceutically acceptable salts of such compounds.
- These new compounds possess inhibitory activity against PDE, V and as such are useful in treating inflammatory conditions, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis or dermatitis in a mammal, especially humans.
- the compounds of the present invention are of the formula (I)
- Y 1 and Y 2 are independently selected from the group consisting of hydrogen, (C C g )alkyl, optionally substituted phenylalkyl having 1 to 6 carbons in the alkyl portion, optionally substituted phenoxyalkyl having 1 to 6 carbons in the alkyl portion, (C 3 - C 7 )cycloalkyl, difluoromethyl, trifluoromethyl, fluoro, chloro, bromo, iodo, -OR 1 and -OR 2 ; wherein the aromatic portion of the optionally substituted phenylalkyl, and the aromatic portion of the optionally substituted phenoxyalkyl are optionally independently substituted with (C 1 -C 4 )alkyl, (C C 4 )alkoxy, halogen or
- R 1 is (C- j -C ⁇ alkyl, phenylalkyl having one to four carbon atoms in the alkyl portion fluoromethyl, difluoromethyl, trifluoromethyl, or -(CH 2 ) q -quinoline wherein q is 1 , 2 or 3;
- R 2 is (C ⁇ C g Jalkyl, (C 3 -C 7 ) cycloalkyl, alkoxyalkyl having 3 to 7 carbons in the alkoxy portion and 2 to 4 carbons in the alkyl portion, optionally substituted phenoxyalkyl having 2 to 6 carbons in the alkyl portion, optionally substituted phenylalkyl having 1 to 6 carbons in the alkyl portion, bicycloalkyl having 6 to 9 carbons or optionally substituted indanyl; wherein the aromatic portion of the optionally substituted phenylalkyl, the aromatic portion of the optionally substituted phenoxyalkyl and the optionally substituted indanyl are optionally substituted with (O,-C 4 )alkyl, (C C 4 )alkoxy, halogen or CF 3 ;
- R 3 is hydrogen, (O,-C 3 )alkyl, fluoro(C 1 -C 3 )alkyl having 1 to 3 fluoro atoms, mono- hydroxyalkyl having 1 to 3 carbons or alkoxyalkyl having 1 to 3 carbons in the alkyl portion and 1 to 3 carbons in the alkoxy portion;
- R 4 is hydrogen, (C ⁇ C ⁇ alkyl, fluoro ⁇ -C ⁇ alkyl having 1 to 3 fluoro atoms, mono- hydroxyalkyi having 1 to 3 carbons, phenyl, alkoxyalkyl having 1 to 3 carbons in the alkyl portion and 1 to 3 carbons in the alkoxy portion, aminoalkyl having 1 to 3
- R 5 is hydrogen or (C 1 -C 3 )a1kyl; or R 3 and R 4 are taken together with the carbon atoms to which they are attached and form a carbocyclic ring having 4 to 7 carbon atoms.
- a preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4- position of the phenyl ring; Y 2 is -OR 2 and is attached to the 3-position of the phenyl ring and m, n, R 1 , R 2 , R 3 , R 4 and R 5 are as defined above for formula (I).
- a more preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4-position of the phenyl ring and Y 2 is -OR 2 and is attached to the 3-position of the phenyl ring wherein R 1 is (C-,-C 4 )alkyl, phenylalkyl having one to four carbon atoms in the alkyl portion or -(CH 2 ) q -quinoline; m is 0; n is 0; and R 2 , R 3 , R 4 and R 5 are as defined above for formula (I).
- Another more preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4-position of the phenyl ring and Y 2 is -OR 2 and is attached to the 3-position of the phenyl ring wherein R 1 is (C C 4 )alkyl, phenylalkyl having one to four carbon atoms in the alkyl portion or -(CH 2 ) q -quinoline; R 2 is phenylalkyl having 1 to 6 carbons in the alkyl portion, (C 3 -C 7 )cycloalkyl, or (C C 3 )alkyl; m is 0; n is 0; and R 3 , R 4 and R 5 are as defined above for formula (I).
- An even more preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4-position of the phenyl ring and Y 2 is -OR 2 and is attached to the 3-position of the phenyl ring wherein R 1 is (C 1 -C 4 )alkyl, phenylalkyl having one to four carbon atoms in the alkyl portion or -(CH 2 ) q -quinoline; R 2 is 5-phenylpentyl, benzyl, cyclopentyl or methyl; m is 0; n is 0; and R 3 , R 4 and R 5 are as defined above for formula (I).
- a particularly preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4-position of the phenyl ring and Y 2 is -OR 2 and is attached to the 3-position of the phenyl ring wherein R 1 is (C.,-C 4 )alkyl, phenylalkyl having one to four carbon atoms in the alkyl portion or -(CH 2 ) q -quinoline; R 2 is 5-phenylpentyl, benzyl, cyclopentyl or methyl; m is 0; n is 0; R 3 is hydrogen and R 4 and R 5 are as defined above for formula
- Another particularly preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4-position of the phenyl ring and Y 2 is -OR 2 and is attached to the 3- position of the phenyl ring wherein R 1 is (C ⁇ C alkyl, phenylalkyl having one to four carbon atoms in the alkyl portion or -(CH 2 ) q -quinoline; R 2 is 5-phenylpentyl, benzyl, cyclopentyl or methyl; m is 0; n is 0; R 3 is hydrogen; R 4 is hydrogen or (C ⁇ C ⁇ alkyl and R 5 is as defined above for formula (I).
- a more particularly preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4-position of the phenyl ring and Y 2 is -OR 2 and is attached to the 3- position of the phenyl ring wherein R 1 is (C j -C ⁇ alkyl, phenylalkyl having one to four carbon atoms in the alkyl portion or -(CH 2 ) q -quinoline; R 2 is 5-phenylpentyl, benzyl, cyclopentyl or methyl; m is 0; n is 0; R 3 is hydrogen; R 4 is hydrogen or (C- ⁇ C g Jalkyl and R 5 is hydrogen or compound or the pharmaceutically acceptable salt thereof of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4-position of the phenyl ring and Y 2 is -OR 2 and is attached to the 3-position of the phenyl
- Another more particularly preferred group of compounds or the pharmaceutically acceptable salts thereof are those compounds of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4-position of the phenyl ring and Y 2 is -OR 2 and is attached to the 3- position of the phenyl ring wherein R 1 is methyl; R 2 is cyclopentyl; m is 0; n is 0; R 3 is hydrogen; R 4 is methyl; and R 5 is hydrogen; and the levorotatory (negative rotation) isomer of a compound or the pharmaceutically acceptable salt thereof of the formula (I) wherein Y 1 is -OR 1 and is attached to the 4-position of the phenyl ring and Y 2 is -OR 2 and is attached to the 3-position of the phenyl ring wherein R 1 is methyl; R 2 is cyclopentyl; m is 0; n is 0; R 3 is hydrogen; R 4 is methyl; and R 5 is hydrogen.
- alkyl encompasses both straight and branched chains.
- the aromatic portion of the optionally substituted phenylalkyl, the aromatic portion of the optionally substituted phenoxyalkyl and the optionally substituted indanyl may be substituted by one or more substituents.
- the compounds of the present invention having the formula (I) are comprised of the racemic, racemic-diastereomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts thereof.
- the compounds of the present invention, having the formula I as defined above, are readily and generally prepared by the following reaction process.
- Y 1 , Y 2 , R 3 , R 4 , m and n are as defined above for the compound of formula (I), and X is an alkyl group.
- the reaction mixture is stirred for about 12 to 24 hours, preferably 16 hours, at room temperature.
- the solvent is evaporated and the residue is worked-up according to methods well known to those skilled in the art.
- Y 1 , Y 2 , R 3 , R 4 , m and n are as defined above for the compound of formula (I), and X is an alkyl group, are synthesized according to the following procedure.
- an inert solvent such as methylene chloride
- Y 2 are as defined above for formula (I). The mixture is allowed to stir for about 2 to 5
- R 3 and R 4 are as defined above for formula I and X is an alkyl group, is added followed by the addition of triethylamine to the mixture and the mixture stirred for about 2 hours more at room temperature.
- the reaction is worked up according to methods well known to those skilled in the art.
- pharmaceutically-acceptable acid addition salts of certain compounds of this invention include, but are not limited to, those formed with HCI, HBr, HNO 3 , H 2 SO 4 , H 3 PO 4 , CH 3 SO 3 H, p-CH 3 C 6 H 4 SO 3 H, CH 3 CO 2 H, gluconic acid, tartaric acid, maleic acid and succinic acid.
- diacid addition salts e.g., the dihydrochloride
- pharmaceutically- acceptable cationic salts of certain compounds of this invention include, but are not limited to, those of sodium, potassium, calcium, magnesium, ammonium, N,N'-dibenzyl- ethylenediamine, N-methylglucamine (meglumine), ethanolamine and diethanolamine.
- the starting materials and reagents required for the synthesis of the compounds of the present invention are readily available, either commercially, according to literature methods, or by methods exemplified in Preparations below.
- the ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit PDE ⁇ and, consequently, demonstrate their effectiveness for treating inflammatory conditions is shown by the following in vitro assays.
- the homogenate is centrifuged at 48,000 x g for 70 minutes at 4°C.
- the supernatant is filtered twice through a 0.22 ⁇ m filter and applied to a Mono-Q FPLC column (Pharmacia LKB Biotechnology, 800 Centennial Avenue, Piscataway, New
- washing buffer 0.5 mL, 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)/0.1 M NaCI, pH 8.5
- HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
- % Inhibition is determined by the formula:
- % Inhibition 1 - average com (test compound) - average com (blank) x 100 average cpm (control) - average cpm (blank)
- IC ⁇ j is defined as that concentration of compound which inhibits 50% of specific hydrolysis of [ 3 H]cAMP to [ 3 H]5'AMP.
- oral dosages of the compounds of formula (I) or the pharmaceutically acceptable salts thereof are generally in the range of from 0.1 - 500 mg daily for an average adult patient (70 kg).
- individual tablets or capsules contain from 0.1 to 50 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. Multiple tablets or capsules may be required to meet the dosage requirements.
- Dosages for intravenous administration are typically within the range of 0.1 to 10 mg per single dose as required.
- the dosage is generally formulated as a 0.1 to 1 % (w/v) solution.
- the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient.
- the above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosage ranges are merited, and all such dosages are within the scope of this invention.
- the compounds of the formula (I) and the pharmaceutically acceptable salts thereof can be administered alone, but will generally be administered in an admixture with a pharmaceutical diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- a pharmaceutical diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovales either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents.
- They may be injected parenterally; for example, intravenously, intramuscularly or subcutaneously.
- parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances; for example, enough salts or glucose to make the solution isotonic.
- topical administration they are best used in the form of solutions, lotions, ointments, salves and the like.
- compositions comprising a compound of the formula (I), or a pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable diluent or carrier which are useful: in inhibiting PDE ⁇ ; in the treatment of inflammatory conditions and in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis and dermatitis in mammals, especially humans.
- This invention also provides methods of inhibiting PDE ⁇ in a mammal in need thereof which methods comprise administering to said mammal a PDE )V inhibiting amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
- This invention further provides a method of treating an inflammatory condition in a mammal in need thereof which comprises administering to said mammal an antiinflammatory amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
- this invention provides a method of treating AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis or shock in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof.
- PREPARATION 1 4-Methoxy-3-(5-phenylpentyloxy)benzaldehyde Oxime
- a mixture of 25.0 g (0.164 mol) of isovanillin, 26.9 g (0.164 mol) of 5-phenyl-1- pentanol, 64.5 g (0.246 mol) of triphenylphosphine and 250 mL of THF was treated dropwise with 42.8 g (0.246 mol) of diethyl azodicarboxylate. The mixture was heated to about 90°C for about 6 hrs and then stirred overnight at RT.
- PREPARATIONS 2 - 4 The following compounds having the formula shown below were prepared, substantially according to the procedure of Preparation 1 , substituting the indicated phenol for isovanillin and the indicated alcohol for 5-phenyl-1 -pentanol. Compounds that were oils were purified by flash chromatography.
- PREPARATIONS 5 - 6 The following compounds having the formula shown below were prepared by condensation of the indicated aldehyde with hydroxylamine hydrochloride, substantially according to the procedure of Preparation 1.
- the R s ows a contaminant which is most likely a product resulting from chlorination of the aromatic ring.
- PREPARATION 22 3-(3.4-Dimethoxyphenyl)-2-isoxazoline-5-carboxylic Acid Methyl Ester
- the mixture was heated to about 50°C and the progress of the reaction was monitored by TLC. Additional 0.4 mL portions of methyl iodide were added at about 1 and 2 h, respectively.
- PREPARATIONS 23 - 25 The following compounds having the formula shown below were prepared, substantially according to the procedure of Preparation 22, substituting the indicated phenol for that of Preparation 15 and the indicated alkylating agent for methyl iodide.
- PREPARATIONS 28-31 The following compounds having the formula shown below were prepared substantially according to the procedure of Preparati 8, however, substituting the compound of Preparation 2 for the compound of Preparation 1 and the indicated olefins for ethyl acrylat
- PREPARATIONS 34-36 The following compounds having the formula shown below were prepared as oils substantially according to the procedure of Preparation 7 substituting the indicated ester for triethylphosphonobutyrate. . ⁇ C 0 2 E t
- PREPARATION 40 (-)-3-(3-Cvclopentyloxy-4-methoxy)phenyl-5-methyl-2-isoxazoline-5-carboxamide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU78218/94A AU687452B2 (en) | 1993-11-26 | 1994-10-26 | Isoxazoline compounds as antiinflammatory agents |
DE69404044T DE69404044T2 (en) | 1993-11-26 | 1994-10-26 | ISOXAZOLINE COMPOUNDS AS AN ANTI-FLAMMING AGENT |
EP94929001A EP0730588B1 (en) | 1993-11-26 | 1994-10-26 | Isoxazoline compounds as antiinflammatory agents |
KR1019960702761A KR0182324B1 (en) | 1993-11-26 | 1994-10-26 | Isoxazoline compounds as anti-inflammatory agents |
BR9408174A BR9408174A (en) | 1993-11-26 | 1994-10-26 | Isoxazoline compounds as anti-inflammatory agents |
PL94314605A PL314605A1 (en) | 1993-11-26 | 1994-10-26 | Isoxazolin compounds as anti-inflammatory agents |
US08/640,944 US5716967A (en) | 1993-11-26 | 1994-10-26 | Isoxazoline compounds as antiinflammatory agents |
NO962127A NO962127D0 (en) | 1993-11-26 | 1996-05-24 | Isoxacin compounds as anti-inflammatory agents |
GR970401783T GR3024133T3 (en) | 1993-11-26 | 1997-07-16 | Isoxazoline compounds as antiinflammatory agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15724893A | 1993-11-26 | 1993-11-26 | |
US08/157,248 | 1993-11-26 | ||
US26208694A | 1994-06-17 | 1994-06-17 | |
US08/262,086 | 1994-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995014681A1 true WO1995014681A1 (en) | 1995-06-01 |
Family
ID=26853945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1994/000333 WO1995014681A1 (en) | 1993-11-26 | 1994-10-26 | Isoxazoline compounds as antiinflammatory agents |
Country Status (24)
Country | Link |
---|---|
US (1) | US5716967A (en) |
EP (1) | EP0730588B1 (en) |
JP (1) | JP2802547B2 (en) |
KR (1) | KR0182324B1 (en) |
CN (1) | CN1046274C (en) |
AT (1) | ATE154932T1 (en) |
AU (1) | AU687452B2 (en) |
BR (1) | BR9408174A (en) |
CA (1) | CA2176255C (en) |
CO (1) | CO4180606A1 (en) |
CZ (1) | CZ283564B6 (en) |
DE (1) | DE69404044T2 (en) |
DK (1) | DK0730588T3 (en) |
EG (1) | EG20693A (en) |
ES (1) | ES2104424T3 (en) |
FI (1) | FI945557A (en) |
GR (1) | GR3024133T3 (en) |
HU (1) | HUT76784A (en) |
IL (1) | IL111670A (en) |
NO (1) | NO962127D0 (en) |
NZ (1) | NZ274244A (en) |
PE (1) | PE33495A1 (en) |
PL (1) | PL314605A1 (en) |
WO (1) | WO1995014681A1 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022977A (en) * | 1997-03-26 | 2000-02-08 | Dupont Pharmaceuticals Company | Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids |
WO2001032175A1 (en) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
EP1389467A1 (en) * | 2001-05-23 | 2004-02-18 | Tanabe Seiyaku Co., Ltd. | Therapeutic compositions for repairing chondropathy |
EP1389468A1 (en) * | 2001-05-23 | 2004-02-18 | Tanabe Seiyaku Co., Ltd. | Compositions for promoting healing of bone fracture |
WO2005021515A2 (en) * | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
WO2005021516A1 (en) * | 2003-08-27 | 2005-03-10 | Lg Life Sciences Ltd. | Caspase inhibitors containing isoxazoline ring |
WO2006085212A3 (en) * | 2005-02-11 | 2006-10-19 | Ranbaxy Lab Ltd | Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv |
WO2006117653A1 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Azole-based phosphodiesterase inhibitors |
US7153824B2 (en) | 2003-04-01 | 2006-12-26 | Applied Research Systems Ars Holding N.V. | Inhibitors of phosphodiesterases in infertility |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP2193808A1 (en) | 1999-08-21 | 2010-06-09 | Nycomed GmbH | Synergistic combination |
EP2223920A2 (en) | 1996-06-19 | 2010-09-01 | Aventis Pharma Limited | Substituted azabicyclic compounds |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
WO2012130798A1 (en) | 2011-03-31 | 2012-10-04 | Bayer Cropscience Ag | Herbicidally and fungicidally active 3-phneylisoxazoline-5-carboxamides and 3-phneylisoxazoline-5-thioamides |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2014081752A1 (en) * | 2012-11-20 | 2014-05-30 | Biogen Idec Ma Inc. | S1p and/or atx modulating agents |
WO2014131024A2 (en) | 2013-02-25 | 2014-08-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015021358A2 (en) | 2013-08-09 | 2015-02-12 | Dominique Charmot | Compounds and methods for inhibiting phosphate transport |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2018228986A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides |
WO2018228985A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxylic acids and esters |
WO2019034602A1 (en) | 2017-08-17 | 2019-02-21 | Bayer Aktiengesellschaft | Herbicidally active 3-phenyl-5-trifluoromethylisoxazoline-5-carboxamides of cyclopentylcarboxylic acids and esters |
WO2019145245A1 (en) | 2018-01-25 | 2019-08-01 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenyl carboxylic acid derivatives |
WO2020182723A1 (en) | 2019-03-12 | 2020-09-17 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters |
WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
JPH09505082A (en) * | 1994-03-09 | 1997-05-20 | ファイザー・インコーポレーテッド | Isoxazoline as an inhibitor of TNF release |
US6245774B1 (en) * | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
US5786354A (en) * | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9713087D0 (en) * | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
DZ3019A1 (en) * | 1999-03-01 | 2005-05-20 | Smithkline Beecham Corp | Use of a pde4 inhibitor in the preparation of a drug against copd. |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
DE60013147T2 (en) * | 1999-09-17 | 2005-08-11 | Lg Chem Investment, Ltd. | CASPASE INHIBITORS |
KR100399361B1 (en) | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | Therapeutic composition comprising caspase inhibitor |
GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
CN100480242C (en) * | 2001-05-29 | 2009-04-22 | 舍林股份公司 | CDK-inhibitory pyrimidines, and production and use thereof as pharmaceutical agents |
EP1411930B1 (en) * | 2001-06-08 | 2013-01-16 | Cytokine Pharmasciences, Inc. | Isoxazoline compounds having mif antagonist activity |
EP2147679B1 (en) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions for blood-brain barrier transport |
AR039385A1 (en) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA |
WO2004043349A2 (en) * | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
SE0302756D0 (en) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
US20070259874A1 (en) * | 2003-11-26 | 2007-11-08 | Palle Venkata P | Phosphodiesterase Inhibitors |
PL1731512T3 (en) | 2004-03-05 | 2015-03-31 | Nissan Chemical Ind Ltd | Isoxazoline-substituted benzamide compound and noxious organism control agent |
MXPA06010793A (en) * | 2004-03-26 | 2006-12-19 | Cytokine Pharmasciences Inc | Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor. |
US20080009535A1 (en) * | 2004-08-30 | 2008-01-10 | Sarala Balachandran | Inhibitors of phosphodiesterase type-IV |
SE0402591D0 (en) * | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
WO2006097273A1 (en) * | 2005-03-15 | 2006-09-21 | Ganial Immunotherapeutics Inc. | Compounds having immunomodulator activity |
WO2006116718A2 (en) | 2005-04-28 | 2006-11-02 | Proteus Biomedical, Inc. | Pharma-informatics system |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
JP2009512711A (en) | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Regulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
AU2007223036A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007249435A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
TW200804383A (en) * | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
KR20090064418A (en) * | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | Combinations containing a 4-acylaminopyridine derivative |
WO2008036678A2 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP2066661A2 (en) * | 2006-09-22 | 2009-06-10 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
US8795627B2 (en) | 2007-03-21 | 2014-08-05 | Raptor Pharmaceuticals Inc. | Treatment of liver disorders by administration of RAP conjugates |
JP5564517B2 (en) | 2009-02-20 | 2014-07-30 | ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ | Glutathione-based drug delivery system |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN102458374A (en) | 2009-05-06 | 2012-05-16 | 实验室护肤股份有限公司 | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
EP2854805B1 (en) | 2012-04-17 | 2019-06-12 | GeneOne Life Science Inc. | Compounds having immunomodulator activity |
CN104812739B (en) * | 2012-09-25 | 2017-12-12 | 拜尔农作物科学股份公司 | The 3 phenyl-isoxazole oxazoline derivatives with herbicide effect |
CN103381157A (en) * | 2013-07-04 | 2013-11-06 | 丁圣雨 | Applications of Chukrasone B in medicines used for treating chronic obstructive lung diseases |
JP6514716B2 (en) * | 2014-04-22 | 2019-05-15 | ノバルティス アーゲー | Isoxazoline hydroxamic acid derivatives as LpxC inhibitors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4731382A (en) * | 1986-12-29 | 1988-03-15 | Bristol-Myers Company | Lipoxygenase inhibitory phenylalkanohydroxamic acids |
EP0378991A1 (en) * | 1989-01-05 | 1990-07-25 | Ciba-Geigy Ag | Certain pyrrolylphenyl-substituted hydroxamic acid derivatives |
JPH03220180A (en) * | 1990-01-24 | 1991-09-27 | Taiho Yakuhin Kogyo Kk | Isoxazoline derivative |
WO1992019589A2 (en) * | 1991-05-03 | 1992-11-12 | Smithkline Beecham Corporation | Lipoxygenase inhibitors |
WO1994002448A1 (en) * | 1992-07-27 | 1994-02-03 | The Wellcome Foundation Limited | Hydroxamic acid derivatives and their use as anti-inflammatory compounds |
WO1994018158A1 (en) * | 1993-02-15 | 1994-08-18 | Pfizer Inc. | Spiroalkylhydroxyureas for use as lipoxygenase inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55104273A (en) * | 1979-02-05 | 1980-08-09 | Sankyo Co Ltd | 4-phenylisoxazole derivative and its preparation |
JPS62103070A (en) * | 1985-10-29 | 1987-05-13 | Mitsui Toatsu Chem Inc | Isoxazoline derivative and plant growth regulator |
US4861798A (en) * | 1986-12-29 | 1989-08-29 | Bristol-Myers Company | Lipoxygenase inhibitory compounds |
US5258397A (en) * | 1988-11-30 | 1993-11-02 | Novapharme | 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions |
FR2639636B1 (en) * | 1988-11-30 | 1994-03-04 | Novapharme | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTICONVULSIVE ACTIVITY, PREPARATION METHOD AND THERAPEUTIC COMPOSITIONS CONTAINING THEM |
DE3939010A1 (en) * | 1989-11-25 | 1991-05-29 | Hoechst Ag | ISOXAZOLINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PLANT PROTECTIVE AGENT |
EP0451790A1 (en) * | 1990-04-12 | 1991-10-16 | Hoechst Aktiengesellschaft | 3,5-disubstituted 2-isoxazolines and isoxazoles, process for their preparation, medicines containing them and their use |
PT100441A (en) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | PIRROLIDINONES, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE |
GB9222253D0 (en) * | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
-
1994
- 1994-10-26 DK DK94929001.9T patent/DK0730588T3/en active
- 1994-10-26 NZ NZ274244A patent/NZ274244A/en unknown
- 1994-10-26 CN CN94194274A patent/CN1046274C/en not_active Expired - Fee Related
- 1994-10-26 AU AU78218/94A patent/AU687452B2/en not_active Ceased
- 1994-10-26 HU HU9601412A patent/HUT76784A/en unknown
- 1994-10-26 ES ES94929001T patent/ES2104424T3/en not_active Expired - Lifetime
- 1994-10-26 WO PCT/IB1994/000333 patent/WO1995014681A1/en active IP Right Grant
- 1994-10-26 CZ CZ961510A patent/CZ283564B6/en not_active IP Right Cessation
- 1994-10-26 US US08/640,944 patent/US5716967A/en not_active Expired - Fee Related
- 1994-10-26 KR KR1019960702761A patent/KR0182324B1/en not_active Application Discontinuation
- 1994-10-26 JP JP7514933A patent/JP2802547B2/en not_active Expired - Lifetime
- 1994-10-26 EP EP94929001A patent/EP0730588B1/en not_active Expired - Lifetime
- 1994-10-26 PL PL94314605A patent/PL314605A1/en unknown
- 1994-10-26 DE DE69404044T patent/DE69404044T2/en not_active Expired - Fee Related
- 1994-10-26 AT AT94929001T patent/ATE154932T1/en not_active IP Right Cessation
- 1994-10-26 CA CA002176255A patent/CA2176255C/en not_active Expired - Fee Related
- 1994-10-26 BR BR9408174A patent/BR9408174A/en not_active Application Discontinuation
- 1994-11-17 IL IL11167094A patent/IL111670A/en not_active IP Right Cessation
- 1994-11-24 EG EG74594A patent/EG20693A/en active
- 1994-11-24 CO CO94053701A patent/CO4180606A1/en unknown
- 1994-11-24 PE PE1994255542A patent/PE33495A1/en not_active Application Discontinuation
- 1994-11-25 FI FI945557A patent/FI945557A/en unknown
-
1996
- 1996-05-24 NO NO962127A patent/NO962127D0/en unknown
-
1997
- 1997-07-16 GR GR970401783T patent/GR3024133T3/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4731382A (en) * | 1986-12-29 | 1988-03-15 | Bristol-Myers Company | Lipoxygenase inhibitory phenylalkanohydroxamic acids |
EP0378991A1 (en) * | 1989-01-05 | 1990-07-25 | Ciba-Geigy Ag | Certain pyrrolylphenyl-substituted hydroxamic acid derivatives |
JPH03220180A (en) * | 1990-01-24 | 1991-09-27 | Taiho Yakuhin Kogyo Kk | Isoxazoline derivative |
WO1992019589A2 (en) * | 1991-05-03 | 1992-11-12 | Smithkline Beecham Corporation | Lipoxygenase inhibitors |
WO1994002448A1 (en) * | 1992-07-27 | 1994-02-03 | The Wellcome Foundation Limited | Hydroxamic acid derivatives and their use as anti-inflammatory compounds |
WO1994018158A1 (en) * | 1993-02-15 | 1994-08-18 | Pfizer Inc. | Spiroalkylhydroxyureas for use as lipoxygenase inhibitors |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 9145, Derwent World Patents Index; AN 91-329223 * |
U. JAHN, TH. WAGNER-JAUREGG: "Wirkungsvergleich saurer Antiphlogistika im Bradykinin-, UV-Erythem- und Rattenpfotenödem-Test", ARZNEIM.-FORSCH., vol. 24, no. 4, 1974, pages 494 - 499 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2223920A2 (en) | 1996-06-19 | 2010-09-01 | Aventis Pharma Limited | Substituted azabicyclic compounds |
US6022977A (en) * | 1997-03-26 | 2000-02-08 | Dupont Pharmaceuticals Company | Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids |
LT4674B (en) | 1997-03-26 | 2000-07-25 | Dupont Pharmaceuticals Company | Lipase catalysed dynamic resolution of izoxazoline thioesters to isoxazoline carboxylic acids |
EP2193808A1 (en) | 1999-08-21 | 2010-06-09 | Nycomed GmbH | Synergistic combination |
US6531498B1 (en) | 1999-11-04 | 2003-03-11 | Merck Patentgesellschaft | Isoxazole derivatives to be used as phosphodiesterase VII inhibitors |
WO2001032175A1 (en) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
EP1389468A1 (en) * | 2001-05-23 | 2004-02-18 | Tanabe Seiyaku Co., Ltd. | Compositions for promoting healing of bone fracture |
US8399466B2 (en) | 2001-05-23 | 2013-03-19 | Mitsubishi Tanabe Pharma Corporation | Composition for regenerative treatment of cartilage disease |
EP1389467A1 (en) * | 2001-05-23 | 2004-02-18 | Tanabe Seiyaku Co., Ltd. | Therapeutic compositions for repairing chondropathy |
US8252794B2 (en) | 2001-05-23 | 2012-08-28 | Mitsubishi Tanabe Pharma Corporation | Composition for regenerative treatment of cartilage disease |
US7659273B2 (en) | 2001-05-23 | 2010-02-09 | Mitsubishi Tanabe Pharma Corporation | Composition for accelerating bone fracture healing |
EP1389467A4 (en) * | 2001-05-23 | 2007-01-10 | Tanabe Seiyaku Co | Therapeutic compositions for repairing chondropathy |
EP1389468A4 (en) * | 2001-05-23 | 2007-01-10 | Tanabe Seiyaku Co | Compositions for promoting healing of bone fracture |
US7153824B2 (en) | 2003-04-01 | 2006-12-26 | Applied Research Systems Ars Holding N.V. | Inhibitors of phosphodiesterases in infertility |
US7557133B2 (en) | 2003-08-27 | 2009-07-07 | Lg Life Sciences Ltd. | Caspase inhibitors containing isoxazoline ring |
WO2005021516A1 (en) * | 2003-08-27 | 2005-03-10 | Lg Life Sciences Ltd. | Caspase inhibitors containing isoxazoline ring |
EA012080B1 (en) * | 2003-08-27 | 2009-08-28 | Эл Джи Лайф Сайенсиз Лтд. | Caspase inhibitors containing isoxazoline ring |
AP2104A (en) * | 2003-08-27 | 2010-02-06 | Lg Life Sciences Ltd | Caspase inhibitors containing isoxazoline ring |
US7825147B2 (en) | 2003-08-29 | 2010-11-02 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
WO2005021515A3 (en) * | 2003-08-29 | 2005-08-25 | Ranbaxy Lab Ltd | Inhibitors of phosphodiesterase type-iv |
WO2005021515A2 (en) * | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2006085212A3 (en) * | 2005-02-11 | 2006-10-19 | Ranbaxy Lab Ltd | Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv |
WO2006117653A1 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Azole-based phosphodiesterase inhibitors |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2923706A1 (en) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
WO2012130798A1 (en) | 2011-03-31 | 2012-10-04 | Bayer Cropscience Ag | Herbicidally and fungicidally active 3-phneylisoxazoline-5-carboxamides and 3-phneylisoxazoline-5-thioamides |
US9078442B2 (en) | 2011-03-31 | 2015-07-14 | Bayer Intellectual Property Gmbh | Herbicidally and fungicidally active 3-phenylisoxazoline-5-carboxamides and 3-phenylisoxazoline-5-thioamides |
EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2014081752A1 (en) * | 2012-11-20 | 2014-05-30 | Biogen Idec Ma Inc. | S1p and/or atx modulating agents |
US9850206B2 (en) | 2012-11-20 | 2017-12-26 | Biogen Ma Inc. | S1P and/or ATX modulating agents |
WO2014131024A2 (en) | 2013-02-25 | 2014-08-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP3718557A2 (en) | 2013-02-25 | 2020-10-07 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015021358A2 (en) | 2013-08-09 | 2015-02-12 | Dominique Charmot | Compounds and methods for inhibiting phosphate transport |
EP3884935A1 (en) | 2013-08-09 | 2021-09-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP3492106A1 (en) | 2013-08-09 | 2019-06-05 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
WO2018228985A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxylic acids and esters |
US11597724B2 (en) | 2017-06-13 | 2023-03-07 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxylic acids and esters |
US11613522B2 (en) | 2017-06-13 | 2023-03-28 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro- and dihydrofurancarboxamides |
WO2018228986A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides |
WO2019034602A1 (en) | 2017-08-17 | 2019-02-21 | Bayer Aktiengesellschaft | Herbicidally active 3-phenyl-5-trifluoromethylisoxazoline-5-carboxamides of cyclopentylcarboxylic acids and esters |
WO2019145245A1 (en) | 2018-01-25 | 2019-08-01 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenyl carboxylic acid derivatives |
WO2020182723A1 (en) | 2019-03-12 | 2020-09-17 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters |
WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Also Published As
Publication number | Publication date |
---|---|
EG20693A (en) | 1999-11-30 |
CZ283564B6 (en) | 1998-05-13 |
JP2802547B2 (en) | 1998-09-24 |
IL111670A0 (en) | 1995-01-24 |
DE69404044T2 (en) | 1997-10-16 |
ATE154932T1 (en) | 1997-07-15 |
NO962127L (en) | 1996-05-24 |
US5716967A (en) | 1998-02-10 |
HU9601412D0 (en) | 1996-07-29 |
FI945557A (en) | 1995-05-27 |
CN1136314A (en) | 1996-11-20 |
BR9408174A (en) | 1997-05-27 |
KR960705795A (en) | 1996-11-08 |
HUT76784A (en) | 1997-11-28 |
ES2104424T3 (en) | 1997-10-01 |
JPH09500147A (en) | 1997-01-07 |
FI945557A0 (en) | 1994-11-25 |
EP0730588A1 (en) | 1996-09-11 |
DK0730588T3 (en) | 1997-12-08 |
AU7821894A (en) | 1995-06-13 |
CA2176255A1 (en) | 1995-06-01 |
CZ151096A3 (en) | 1997-01-15 |
NO962127D0 (en) | 1996-05-24 |
PL314605A1 (en) | 1996-09-16 |
CN1046274C (en) | 1999-11-10 |
CO4180606A1 (en) | 1995-06-07 |
DE69404044D1 (en) | 1997-08-07 |
CA2176255C (en) | 1999-02-23 |
AU687452B2 (en) | 1998-02-26 |
NZ274244A (en) | 1997-09-22 |
KR0182324B1 (en) | 1999-05-01 |
EP0730588B1 (en) | 1997-07-02 |
GR3024133T3 (en) | 1997-10-31 |
IL111670A (en) | 1998-08-16 |
PE33495A1 (en) | 1995-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU687452B2 (en) | Isoxazoline compounds as antiinflammatory agents | |
US6114367A (en) | Isoxazoline compounds as inhibitors of TNF release | |
EP0730587B1 (en) | 3-phenyl-2-isoxazolines as antiinflammatory agents | |
AU728329B2 (en) | New substituted biphenyl or phenylpyridine compounds, a process for their preparation and pharmaceutical compositions containing them | |
US8124778B2 (en) | Tricyclic inhibitors of fatty acid amide hydrolase | |
US5326770A (en) | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals | |
JP2001509166A (en) | Thiazolebenzenesulfonamide as a beta lower agonist for the treatment of diabetes and obesity | |
BRPI0710231A2 (en) | compound, pharmaceutical composition, and intermediate for the preparation of a compound | |
EP1581214A1 (en) | 4,5-diarylthiazole derivatives as cb-1 ligands | |
KR20080072688A (en) | Oxadiazole derivatives with crth2 receptor activity | |
JP3188715B2 (en) | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthase | |
JP7381578B2 (en) | Bicyclic inhibitor of histone deacetylase | |
WO2014121633A1 (en) | Derivative of homoserine lactone, and preparation method and use thereof | |
JPH0789953A (en) | Pharmaceutical compound | |
WO2023212237A1 (en) | Compositions useful for modulating splicing | |
WO2012158399A1 (en) | Condensed 2 - carbamoylpyridazinones as potassium channel modulators | |
PAZHAM et al. | International Bureau |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94194274.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU JP KR NO NZ PL RU US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 274244 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994929001 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2176255 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08640944 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1996-1510 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1994929001 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-1510 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994929001 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1996-1510 Country of ref document: CZ |